IBDEI09X ; ; 09-MAY-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 09, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,13302,0)
 ;;=209.02^^83^835^24
 ;;^UTILITY(U,$J,358.3,13302,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13302,1,1,0)
 ;;=1^209.02
 ;;^UTILITY(U,$J,358.3,13302,1,8,0)
 ;;=8^Mal Carcinoid Tumor,Jejunum
 ;;^UTILITY(U,$J,358.3,13302,2)
 ;;=^336491
 ;;^UTILITY(U,$J,358.3,13303,0)
 ;;=209.03^^83^835^23
 ;;^UTILITY(U,$J,358.3,13303,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13303,1,1,0)
 ;;=1^209.03
 ;;^UTILITY(U,$J,358.3,13303,1,8,0)
 ;;=8^Mal Carcinoid Tumor,Ileum
 ;;^UTILITY(U,$J,358.3,13303,2)
 ;;=^336492
 ;;^UTILITY(U,$J,358.3,13304,0)
 ;;=204.00^^83^836^1
 ;;^UTILITY(U,$J,358.3,13304,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13304,1,1,0)
 ;;=1^204.00
 ;;^UTILITY(U,$J,358.3,13304,1,8,0)
 ;;=8^ALL w/o Remission
 ;;^UTILITY(U,$J,358.3,13304,2)
 ;;=^267521
 ;;^UTILITY(U,$J,358.3,13305,0)
 ;;=204.01^^83^836^3
 ;;^UTILITY(U,$J,358.3,13305,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13305,1,1,0)
 ;;=1^204.01
 ;;^UTILITY(U,$J,358.3,13305,1,8,0)
 ;;=8^ALL,in Remission
 ;;^UTILITY(U,$J,358.3,13305,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,13306,0)
 ;;=204.10^^83^836^5
 ;;^UTILITY(U,$J,358.3,13306,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13306,1,1,0)
 ;;=1^204.10
 ;;^UTILITY(U,$J,358.3,13306,1,8,0)
 ;;=8^CLL w/o Remission
 ;;^UTILITY(U,$J,358.3,13306,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,13307,0)
 ;;=204.11^^83^836^7
 ;;^UTILITY(U,$J,358.3,13307,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13307,1,1,0)
 ;;=1^204.11
 ;;^UTILITY(U,$J,358.3,13307,1,8,0)
 ;;=8^CLL,in Remission
 ;;^UTILITY(U,$J,358.3,13307,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,13308,0)
 ;;=201.90^^83^836^11
 ;;^UTILITY(U,$J,358.3,13308,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13308,1,1,0)
 ;;=1^201.90
 ;;^UTILITY(U,$J,358.3,13308,1,8,0)
 ;;=8^Hodgkin's Lymphoma,Unspec Type
 ;;^UTILITY(U,$J,358.3,13308,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,13309,0)
 ;;=202.00^^83^836^19
 ;;^UTILITY(U,$J,358.3,13309,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13309,1,1,0)
 ;;=1^202.00
 ;;^UTILITY(U,$J,358.3,13309,1,8,0)
 ;;=8^Lymphoma,Low-Grade (Nodular)
 ;;^UTILITY(U,$J,358.3,13309,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,13310,0)
 ;;=200.20^^83^836^16
 ;;^UTILITY(U,$J,358.3,13310,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13310,1,1,0)
 ;;=1^200.20
 ;;^UTILITY(U,$J,358.3,13310,1,8,0)
 ;;=8^Lymphoma,Burkitts
 ;;^UTILITY(U,$J,358.3,13310,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,13311,0)
 ;;=202.10^^83^836^29
 ;;^UTILITY(U,$J,358.3,13311,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13311,1,1,0)
 ;;=1^202.10
 ;;^UTILITY(U,$J,358.3,13311,1,8,0)
 ;;=8^Mycosis Fungoides
 ;;^UTILITY(U,$J,358.3,13311,2)
 ;;=^80360
 ;;^UTILITY(U,$J,358.3,13312,0)
 ;;=273.3^^83^836^21
 ;;^UTILITY(U,$J,358.3,13312,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13312,1,1,0)
 ;;=1^273.3
 ;;^UTILITY(U,$J,358.3,13312,1,8,0)
 ;;=8^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,13312,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,13313,0)
 ;;=203.00^^83^836^28
 ;;^UTILITY(U,$J,358.3,13313,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13313,1,1,0)
 ;;=1^203.00
 ;;^UTILITY(U,$J,358.3,13313,1,8,0)
 ;;=8^Multiple Myeloma,W/O Remission
 ;;^UTILITY(U,$J,358.3,13313,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,13314,0)
 ;;=203.01^^83^836^27
 ;;^UTILITY(U,$J,358.3,13314,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13314,1,1,0)
 ;;=1^203.01
 ;;^UTILITY(U,$J,358.3,13314,1,8,0)
 ;;=8^Multiple Myeloma,In Remission
 ;;^UTILITY(U,$J,358.3,13314,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,13315,0)
 ;;=202.40^^83^836^8
 ;;^UTILITY(U,$J,358.3,13315,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13315,1,1,0)
 ;;=1^202.40
 ;;^UTILITY(U,$J,358.3,13315,1,8,0)
 ;;=8^Hairy-Cell Leukemia
 ;;^UTILITY(U,$J,358.3,13315,2)
 ;;=^69587
 ;;^UTILITY(U,$J,358.3,13316,0)
 ;;=200.10^^83^836^18
 ;;^UTILITY(U,$J,358.3,13316,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13316,1,1,0)
 ;;=1^200.10
 ;;^UTILITY(U,$J,358.3,13316,1,8,0)
 ;;=8^Lymphoma,Int/High (Diffuse)
 ;;^UTILITY(U,$J,358.3,13316,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,13317,0)
 ;;=273.1^^83^836^25
 ;;^UTILITY(U,$J,358.3,13317,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13317,1,1,0)
 ;;=1^273.1
 ;;^UTILITY(U,$J,358.3,13317,1,8,0)
 ;;=8^Monoclon Paraproteinemia
 ;;^UTILITY(U,$J,358.3,13317,2)
 ;;=^78888
 ;;^UTILITY(U,$J,358.3,13318,0)
 ;;=238.79^^83^836^20
 ;;^UTILITY(U,$J,358.3,13318,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13318,1,1,0)
 ;;=1^238.79
 ;;^UTILITY(U,$J,358.3,13318,1,8,0)
 ;;=8^Lymphoproliferat Dis
 ;;^UTILITY(U,$J,358.3,13318,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,13319,0)
 ;;=202.90^^83^836^17
 ;;^UTILITY(U,$J,358.3,13319,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13319,1,1,0)
 ;;=1^202.90
 ;;^UTILITY(U,$J,358.3,13319,1,8,0)
 ;;=8^Lymphoma,Diffuse,Unspec Site
 ;;^UTILITY(U,$J,358.3,13319,2)
 ;;=^267504
 ;;^UTILITY(U,$J,358.3,13320,0)
 ;;=200.30^^83^836^23
 ;;^UTILITY(U,$J,358.3,13320,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13320,1,1,0)
 ;;=1^200.30
 ;;^UTILITY(U,$J,358.3,13320,1,8,0)
 ;;=8^Marginal Zone Lymphoma
 ;;^UTILITY(U,$J,358.3,13320,2)
 ;;=^335296
 ;;^UTILITY(U,$J,358.3,13321,0)
 ;;=200.40^^83^836^22
 ;;^UTILITY(U,$J,358.3,13321,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13321,1,1,0)
 ;;=1^200.40
 ;;^UTILITY(U,$J,358.3,13321,1,8,0)
 ;;=8^Mantle Cell Lymphoma
 ;;^UTILITY(U,$J,358.3,13321,2)
 ;;=^335297
 ;;^UTILITY(U,$J,358.3,13322,0)
 ;;=200.50^^83^836^32
 ;;^UTILITY(U,$J,358.3,13322,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13322,1,1,0)
 ;;=1^200.50
 ;;^UTILITY(U,$J,358.3,13322,1,8,0)
 ;;=8^Prim CNS Lymphoma
 ;;^UTILITY(U,$J,358.3,13322,2)
 ;;=^335298
 ;;^UTILITY(U,$J,358.3,13323,0)
 ;;=200.60^^83^836^4
 ;;^UTILITY(U,$J,358.3,13323,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13323,1,1,0)
 ;;=1^200.60
 ;;^UTILITY(U,$J,358.3,13323,1,8,0)
 ;;=8^Anaplastic Large Cell Lymphoma
 ;;^UTILITY(U,$J,358.3,13323,2)
 ;;=^335299
 ;;^UTILITY(U,$J,358.3,13324,0)
 ;;=200.70^^83^836^13
 ;;^UTILITY(U,$J,358.3,13324,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13324,1,1,0)
 ;;=1^200.70
 ;;^UTILITY(U,$J,358.3,13324,1,8,0)
 ;;=8^Large Cell Lymphoma
 ;;^UTILITY(U,$J,358.3,13324,2)
 ;;=^335300
 ;;^UTILITY(U,$J,358.3,13325,0)
 ;;=200.80^^83^836^31
 ;;^UTILITY(U,$J,358.3,13325,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13325,1,1,0)
 ;;=1^200.80
 ;;^UTILITY(U,$J,358.3,13325,1,8,0)
 ;;=8^Oth Named Variants
 ;;^UTILITY(U,$J,358.3,13325,2)
 ;;=^176827
 ;;^UTILITY(U,$J,358.3,13326,0)
 ;;=201.00^^83^836^9
 ;;^UTILITY(U,$J,358.3,13326,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13326,1,1,0)
 ;;=1^201.00
 ;;^UTILITY(U,$J,358.3,13326,1,8,0)
 ;;=8^Hodgkin's Disease
 ;;^UTILITY(U,$J,358.3,13326,2)
 ;;=^265557
 ;;^UTILITY(U,$J,358.3,13327,0)
 ;;=201.10^^83^836^10
 ;;^UTILITY(U,$J,358.3,13327,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13327,1,1,0)
 ;;=1^201.10
 ;;^UTILITY(U,$J,358.3,13327,1,8,0)
 ;;=8^Hodgkin's Granuloma
 ;;^UTILITY(U,$J,358.3,13327,2)
 ;;=^58273
 ;;^UTILITY(U,$J,358.3,13328,0)
 ;;=201.20^^83^836^12
 ;;^UTILITY(U,$J,358.3,13328,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13328,1,1,0)
 ;;=1^201.20
 ;;^UTILITY(U,$J,358.3,13328,1,8,0)
 ;;=8^Hodgkin's Sarcoma
 ;;^UTILITY(U,$J,358.3,13328,2)
 ;;=^265560
 ;;^UTILITY(U,$J,358.3,13329,0)
 ;;=201.40^^83^836^15
 ;;^UTILITY(U,$J,358.3,13329,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13329,1,1,0)
 ;;=1^201.40
 ;;^UTILITY(U,$J,358.3,13329,1,8,0)
 ;;=8^Lymphocytic-Histiocytic
 ;;^UTILITY(U,$J,358.3,13329,2)
 ;;=^265549
 ;;^UTILITY(U,$J,358.3,13330,0)
 ;;=201.50^^83^836^30
 ;;^UTILITY(U,$J,358.3,13330,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13330,1,1,0)
 ;;=1^201.50
 ;;^UTILITY(U,$J,358.3,13330,1,8,0)
 ;;=8^Nodular Sclerosis
 ;;^UTILITY(U,$J,358.3,13330,2)
 ;;=^265555
 ;;^UTILITY(U,$J,358.3,13331,0)
 ;;=201.60^^83^836^24
 ;;^UTILITY(U,$J,358.3,13331,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13331,1,1,0)
 ;;=1^201.60
 ;;^UTILITY(U,$J,358.3,13331,1,8,0)
 ;;=8^Mixed Cellularity
 ;;^UTILITY(U,$J,358.3,13331,2)
 ;;=^265551
 ;;^UTILITY(U,$J,358.3,13332,0)
 ;;=201.70^^83^836^14
 ;;^UTILITY(U,$J,358.3,13332,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13332,1,1,0)
 ;;=1^201.70
 ;;^UTILITY(U,$J,358.3,13332,1,8,0)
 ;;=8^Lymphocytic Depletion
 ;;^UTILITY(U,$J,358.3,13332,2)
 ;;=^265553
 ;;^UTILITY(U,$J,358.3,13333,0)
 ;;=203.02^^83^836^26
 ;;^UTILITY(U,$J,358.3,13333,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13333,1,1,0)
 ;;=1^203.02
 ;;^UTILITY(U,$J,358.3,13333,1,8,0)
 ;;=8^Multiple Myeloma in Relapse
 ;;^UTILITY(U,$J,358.3,13333,2)
 ;;=^336462
 ;;^UTILITY(U,$J,358.3,13334,0)
 ;;=204.02^^83^836^2
 ;;^UTILITY(U,$J,358.3,13334,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13334,1,1,0)
 ;;=1^204.02
 ;;^UTILITY(U,$J,358.3,13334,1,8,0)
 ;;=8^ALL,in Relapse
 ;;^UTILITY(U,$J,358.3,13334,2)
 ;;=^336465
 ;;^UTILITY(U,$J,358.3,13335,0)
 ;;=204.12^^83^836^6
 ;;^UTILITY(U,$J,358.3,13335,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13335,1,1,0)
 ;;=1^204.12
 ;;^UTILITY(U,$J,358.3,13335,1,8,0)
 ;;=8^CLL,in Relapse
 ;;^UTILITY(U,$J,358.3,13335,2)
 ;;=^336466
 ;;^UTILITY(U,$J,358.3,13336,0)
 ;;=156.2^^83^837^1
 ;;^UTILITY(U,$J,358.3,13336,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13336,1,1,0)
 ;;=1^156.2
 ;;^UTILITY(U,$J,358.3,13336,1,8,0)
 ;;=8^Malig Neo Ampulla of Vater
 ;;^UTILITY(U,$J,358.3,13336,2)
 ;;=^267100
 ;;^UTILITY(U,$J,358.3,13337,0)
 ;;=154.3^^83^837^2
 ;;^UTILITY(U,$J,358.3,13337,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13337,1,1,0)
 ;;=1^154.3
 ;;^UTILITY(U,$J,358.3,13337,1,8,0)
 ;;=8^Malig Neo Anus
 ;;^UTILITY(U,$J,358.3,13337,2)
 ;;=^267092
 ;;^UTILITY(U,$J,358.3,13338,0)
 ;;=156.1^^83^837^3
 ;;^UTILITY(U,$J,358.3,13338,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13338,1,1,0)
 ;;=1^156.1
 ;;^UTILITY(U,$J,358.3,13338,1,8,0)
 ;;=8^Malig Neo Bile Ducts
 ;;^UTILITY(U,$J,358.3,13338,2)
 ;;=^267099
 ;;^UTILITY(U,$J,358.3,13339,0)
 ;;=153.9^^83^837^5
 ;;^UTILITY(U,$J,358.3,13339,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,13339,1,1,0)
 ;;=1^153.9
